Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Cash & Equivalents	70.25	31.16
Short-Term Investments	77.31	0
Cash & Cash Equivalents	147.56	31.16
Cash Growth	373.58%	-
Other Current Assets	3.31	0.11
Total Current Assets	150.87	31.27
Property, Plant & Equipment	4	0.34
Other Long-Term Assets	0.55	0
Total Long-Term Assets	4.55	0.34
Total Assets	155.42	31.6
Accounts Payable	2.5	1.45
Current Debt	0.67	0
Other Current Liabilities	5.63	0.21
Total Current Liabilities	8.8	1.66
Long-Term Debt	1.48	0
Other Long-Term Liabilities	4.2	10.44
Total Long-Term Liabilities	5.68	10.44
Total Liabilities	14.48	12.1
Total Debt	2.15	0
Retained Earnings	-45.44	-10.65
Comprehensive Income	0	0
Shareholders' Equity	-25.63	-10.06
Net Cash / Debt	145.42	31.16
Net Cash / Debt Growth	366.69%	-
Net Cash Per Share	11.28	4.68
Working Capital	142.07	29.61
Book Value Per Share	-1.99	-1.51

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).